Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels

Nephron

Volumn 92, Issue 4, 2002, Pages 817-823

  Preston, Gloria A ^a   Barrett, Cheri V ^a   Alcorta, David A ^a   Hogan, Susan L ^a   Dinwiddie, Lesley ^a   Jennette, J Charles ^a   Falk, Ronald J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

C reactive protein; Hemodialysis; Inflammation; Interleukin 6; Matrix metalloproteinases; Peritoneal dialysis

Indexed keywords

C REACTIVE PROTEIN; GELATINASE A; INTERLEUKIN 6; STROMELYSIN;

ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULOSCLEROSIS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CREATININE; FEMALE; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; PERITONEAL DIALYSIS; RENAL DIALYSIS;

EID: 0036972170     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065464     Document Type: Article

References (39)

1. Pannen BH, Robotham JL: The acute-phase response. New Horiz 1995;3:183-197.
2. Kaysen GA, Stevenson FT, Depner TA: Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 1997;29:658-668.
3. Yeun JY, Kaysen GA: Acute phase proteins and peritoneal dialysate albumin loss are the main determinants of serum albumin in peritoneal dialysis patients. Am J Kidney Dis 1997; 30:923-927.
4. Owen WF, Lowrie EG: C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998;54:627-636.
5. Sharma AP, Gupta A, Sharma RK, Agarwal DK, Sural S, Wardhe DJ: Does serum albumin at start of continuous ambulatory peritoneal dialysis (CAPD) or its drop during CAPD determine patient outcome? [In process citation]. Adv Perit Dial 2000;16:119-122.
6. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-658.
7. Stahl WM: Acute phase protein response to tissue injury. Crit Care Med 1987;15:545-550.
8. Dowton SB, Colten HR: Acute phase reactants in inflammation and infection. Semin Hematol 1988;25:84-90.
9. Zhang D, Jiang SL, Rzewnicki D, Samols D, Kushner I: The effect of interleukin-1 on C-reactive protein expression in Hep3B cells is exerted at the transcriptional level. Biochem J 1995;310:143-148.
10. Ito A, Itoh Y, Sasaguri Y, Morimatsu M, Mori Y: Effects of interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts. Arthritis Rheum 1992;35:1197-1201.
11. Nakamoto Y, Imai H, Yasuda T, Wakui H, Miura AB: A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome. Nephrol Dial Transplant 1999;14:2370-2378.
12. Kaul H, Girndt M, Sester U, Sester M, Kohler H: Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease. Am J Kidney Dis 2000;35:611-616.
13. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T et al: Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castle-man's disease. Blood 1989;74:1360-1367.
14. Henderson LW: Symptomatic hypotension during hemodialysis. Kidney Int 1980;17:571-576.
15. Wang P, Ba ZF, Cioffi WG, Bland KI, Chaudry IH: Hepatocellular dysfunction after severe hypotension in the absence of blood loss is associated with the increased IL-6 and PGE2. J Surg Res 1998;80:136-142.
16. Borden P, Heller RA: Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryot Gene Expr 1997;7:159-178.
17. Kossakowska AE, Edwards DR, Prusinkiewicz C, Zhang MC, Guo D, Urbanski SJ, Grogan T, Marquez LA, Janowska-Wieczorek A: Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 1999;94:2080-2089.
18. Davies M, Martin J, Thomas GJ, Lovett DH: Proteinases and glomerular matrix turnover. Kidney Int 1992;41:671-678.
19. Akiyama K, Shikata K, Sugimoto H, Matsuda M, Shikata Y, Fujimoto N, Obata K, Matsui H, Makino H: Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis. Res Commun Mol Pathol Pharmacol 1997;95: 115-128.
20. Norman JT, Lewis MP: Matrix metalloproteinases (MMPs) in renal fibrosis. Kidney Int Suppl 1996;54:S61-63.
21. Turck J, Pollock AS, Lovett DH: Gelatinase A is a glomerular mesangial cell growth and differentiation factor. Kidney Int 1997;51:1397-1400.
22. Turck J, Pollock AS, Lee LK, Marti HP, Lovett DH: Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem 1996; 271:15074-15083.
23. Lovett DH, Johnson RJ, Marti HP, Martin J, Davies M, Couser WG: Structural characterization of the mesangial cell type IV collagenase and enhanced expression in a model of immune complex-mediated glomerulonephritis. Am J Pathol 1992;141:85-98.
24. Kotajima L, Aotsuka S, Fujimani M, Okawa-Takatsuji M, Kinoshita M, Sumiya, M, Obata K: Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis. Clin Exp Rheumatol 1998;16:409-415.
25. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503.
26. Bini A, Itoh Y, Kudryk BJ, Nagase H: Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): Hydrolysis of the gamma Gly 404-Ala 405 peptide bond. Biochemistry 1996;35:13056-13063.
27. Ye S, Humphries S, Henney A: Matrix metalloproteinases: Implication in vascular matrix remodelling during atherogenesis. Clin Sci (Colch) 1998;94:103-110.
28. Shapiro SD: Matrix metalloproteinase degradation of extracellular matrix: Biological consequences. Curr Opin Cell Biol 1998;10:602-608.
29. Ribbens C, Andre B, Jaspar JM, Kaye O, Kaiser MJ, De Groote D, Malaise MG: Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 2000;27:888-893.
30. Ribbens C, Martin Y, Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG: Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: Relationship with synovitis and steroid treatment. Ann Rheum Dis 2002;61:161-166.
31. Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ, van Hinsbergh VW: Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells: Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J 1993;296:803-809.
32. McIntyre C, Harper I, Macdougall IC, Raine AE, Williams A, Baker LR: Serum C-reactive protein as a marker for infection and inflammation in regular dialysis patients. Clin Nephrol 1997;48:371-374.
33. Solomon A, Li DQ, Lee SB, Tseng SC: Regulation of collagenase, stromelysin, and urokinase-type plasminogen activator in primary pterygium body fibroblasts by inflammatory cytokines. Invest Ophthalmol Vis Sci 2000;41:2154-2163.
34. Zbroch E, Malyszko J, Wolczynski S, Hryszko T, Mysliwiec M: Concentration of leptin in patients on hemodialysis and peritoneal dialysis. Pol Arch Med Wewn 1999;101:503-508.
35. Baumann H, Jahreis GP, Morella KK: Interaction of cytokine- and glucocorticoid-response elements of acute-phase plasma protein genes. Importance of glucocorticoid receptor level and cell type for regulation of the elements from rat alpha 1-acid glycoprotein and beta-fibrinogen genes. J Biol Chem 1990;265: 22275-22281.
36. Baumann H, Jahreis GP, Morella KK, Won KA, Pruitt SC, Jones VE, Prowse KR: Transcriptional regulation through cytokine and glucocorticoid response elements of rat acute phase plasma protein genes by C/EBP and JunB. J Biol Chem 1991;266:20390-20399.
37. Szalai AJ, van Ginkel FW, Wang Y, McGhee JR, Volanakis JE: Complement-dependent acute-phase expression of C-reactive protein and serum amyloid P-component. J Immunol 2000;165:1030-1035.
38. Lonnemann G: The quality of dialysate: An integrated approach. Kidney Int 2000;58 (suppl 76):S112-119.
39. Rodrigo E, Lopez-Hoyos M, Escallada R, Fernandez-Fresnedo G, Ruiz JC, Pinera C, Cotorruelo, JG, Zubimendi, JA, de Francisco AL, Arias M: Circulating levels of matrix metalloproteinases MMP-3 and MMP-2 in renal transplant recipients with chronic transplant nephropathy. Nephrol Dial Transplant 2000;15: 2041-2045.